Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Letter of Medical Necessity
Biktarvy (bictegravir/FTC/TAF) is a guideline-recommended first-line ARV regimen. PA denials are usually correctable with baseline labs and resistance testing documentation.
FDA-Approved Indications
- ● HIV-1 in treatment-naïve and virologically suppressed adults and pediatrics ≥14 kg
Why Biktarvy Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Resistance testing not documented
- 2. Renal function not on file
- 3. HBV co-infection status missing
What to Include in a Biktarvy Letter of Medical Necessity
Document HIV-1 confirmation, viral load, CD4 count, resistance testing, HBV co-infection status, renal function (eGFR), and adherence considerations.
Key clinical evidence to cite:
- ✓ Studies 1489, 1490, 1844, 1878
Relevant guidelines:
- 📖 DHHS HIV Guidelines
- 📖 IAS-USA Recommendations
Biktarvy Prior Authorization Criteria
Standard criteria across major US payers for Biktarvy. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Biktarvy
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Biktarvy Prior Authorization FAQ
Why was my Biktarvy prior authorization denied?
The most common denial reasons for Biktarvy are: Resistance testing not documented; Renal function not on file; HBV co-infection status missing.
What should a Biktarvy Letter of Medical Necessity include?
Document HIV-1 confirmation, viral load, CD4 count, resistance testing, HBV co-infection status, renal function (eGFR), and adherence considerations.
Which payers cover Biktarvy?
Biktarvy is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.